KPF
COCHW icon

K2 Principal Fund’s Envoy Medical Warrant COCHW Stock Holding History

K2 Principal Fund’s Portfolio COCHW Stock Details COCHW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$39K – 310
2021
Q4 		$39K Buy
+50,000
New +$36.6K ﹤0.01% 358

Other funds holding COCHW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

K2 Principal Fund's COCHW Position: Q1 2022 in Review

K2 Principal Fund sold out of Envoy Medical Warrant (COCHW) in Q1 2022, closing a stake of 50,000 shares — an estimated $39K sold.

K2 Principal Fund first reported a position in COCHW in Q4 2021 and held it in 1 quarter. The position peaked at $39K in Q4 2021. 53 funds tracked by Wall St. Rank hold COCHW as of Q1 2022.

  • K2 Principal Fund reported no remaining Envoy Medical Warrant position as of Q1 2022 after selling out during the quarter.
  • K2 Principal Fund sold 50,000 Envoy Medical Warrant shares in Q1 2022, an estimated $39K.
  • K2 Principal Fund first reported a position in Envoy Medical Warrant in Q4 2021 and held it in 1 quarter.
  • K2 Principal Fund's Envoy Medical Warrant position peaked at $39K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Envoy Medical Warrant as of Q1 2022.

Based on K2 Principal Fund's 13F filing for Q1 2022, filed 16 May 2022.